13F Holdings
中文EN

IRD Opus Genetics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1228627 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.9%
TTM net income YoY-100.4%
TTM EPS YoY20.4%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-777.7%
Net margin-1,726.7%
FCF margin—
EBITDA margin-776.9%

Returns

ROE-615.6%
ROA-208.0%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets59.7%
Debt / equity0.93x
Current ratio9.65x
Interest coverage-217.47x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-134.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$14.20M$10.99M$19.05M$39.85M$589,000
R&D expense$30.81M$26.85M$17.65M$14.36M$15.17M
SG&A expense$21.98M$18.21M$11.96M$7.27M$8.12M
Operating income-$38.60M-$62.07M-$10.56M$18.23M-$22.70M
Interest expense$129,000$0$0$9,000$2,000
Pretax income-$49.59M-$57.53M-$9.97M$18.20M-$56.69M
Income tax$0$0$12,000$315,000$0
Net income-$49.59M-$57.53M-$9.99M$17.89M-$56.69M
EBITDA-$38.55M-$62.06M-$10.56M$18.23M-$22.70M
EPS (basic)-0.80-2.15-0.460.90-3.82
EPS (diluted)-0.80-2.15-0.460.87-3.82
Weighted avg. shares (diluted)62.22M26.72M21.59M20.60M14.85M
Balance sheet
Cash & equivalents$45.09M$30.32M$50.50M$42.63M$24.53M
Short-term investments$0$2,000$15,000$49,000$219,000
Receivables$2.00M$3.56M$926,000$1.30M$0
Current assets$50.04M$36.61M$53.95M$48.99M$26.07M
PP&E, net$199,000$252,000$0$6,000$10,000
Total assets$50.24M$36.86M$53.95M$48.99M$26.08M
Current liabilities$7.78M$11.29M$4.04M$2.75M$3.85M
Short-term debt———$0$538,000
Long-term debt$1.13M$0———
Total debt$1.13M$0———
Total liabilities$34.90M$11.29M$4.04M$2.75M$3.85M
Shareholders' equity$15.35M$6.72M$49.91M$46.24M$22.22M
Net debt-$43.96M-$30.32M———
Shares outstanding69.89M31.57M23.98M20.86M18.85M
Cash flow statement
Operating cash flow-$35.25M-$25.58M-$1.11M$14.31M-$19.37M
Investing cash flow$0$1.21M$0$0-$100,000
Financing cash flow$50.02M$4.19M$8.98M$3.79M$27.61M
Depreciation & amortization$53,000$10,000$6,000$4,000$4,000
Stock-based compensation$3.40M$3.36M$3.51M$1.81M$1.91M

Free plan shows the latest 5 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.